文献速递白血病造血干细胞移植与细胞治疗

含克拉屈滨预处理异基因造血干细胞移植治疗难治/复发急性髓系白血病的临床观察

[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

该回顾性研究分析12例接受含克拉屈滨序贯白消安预处理方案allo-HSCT的难治/复发AML患者,11例获得造血重建,预期1年OS为(71.1±1.8)%、DFS为(62.2±1.8)%。结论认为该方案可作为难治/复发AML的可选治疗方案。

要点

  • 含克拉屈滨序贯白消安预处理allo-HSCT在12例难治/复发AML中可行。
  • 11例获得造血重建,中性粒细胞和血小板中位植入时间分别为15天和19天。
  • 预期1年OS为(71.1±1.8)%,DFS为(62.2±1.8)%。

核心结论

  • 含克拉屈滨序贯白消安预处理的allo-HSCT可作为难治/复发AML患者的可选治疗方案。

研究设计与样本

  • 回顾性分析12例接受含克拉屈滨预处理allo-HSCT的难治/复发AML患者临床资料。
  • 12例中男9例、女3例,中位年龄36(27~50)岁;亲缘全相合供者移植3例,无关供者移植1例,单倍型移植8例。
  • 移植前部分缓解9例、未缓解3例,移植前化疗中位疗程6(2~13)个。

主要发现

  • 11例获得造血重建,1例发生原发植入失败;中性粒细胞植入时间15(15~21)d,血小板植入时间19(17~30)d。
  • 预处理中均未发生肝静脉闭塞病,2例发生出血性膀胱炎;移植过程中8例出现发热,经抗感染治疗后好转。
  • 3例发生Ⅱ度急性GVHD;至随访截止9例存活患者中8例发生慢性局限型GVHD。
  • 中位随访8(4~12)个月,2例分别在移植后6、12个月复发;预期1年OS为(71.1±1.8)%,DFS为(62.2±1.8)%。

关键数值与推荐

  • 预处理方案:司莫司汀250 mg·m⁻²·d⁻¹,-7 d;克拉屈滨5 mg·m⁻²·d⁻¹,-6 d~-2 d;阿糖胞苷2 g·m⁻²·d⁻¹,-6 d~-2 d;白消安3.2 mg·m⁻²·d⁻¹,-6 d~-3 d。
  • 兔抗人胸腺细胞免疫球蛋白1.5 mg·m⁻²·d⁻¹(无关供者移植)或2.0~2.5 mg·m⁻²·d⁻¹(单倍型移植),-4 d~-1 d。

临床怎么用

  • 对难治/复发AML患者,可考虑含克拉屈滨序贯白消安预处理allo-HSCT,并关注植入失败、出血性膀胱炎和GVHD等并发症。

局限性

  • 回顾性分析、样本量仅12例,中位随访8(4~12)个月,证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) containing cladribine sequential busulfan regimen for refractory/relapsed acute myeloid leukemia (AML) . Methods: The clinical data of 12 refractory/relapsed AML patients received allo-HSCT with cladribine sequential busulfan regimen. Results: ① Of the 12 patients, 9 were males and 3 females, with a median age of 36 (27-50) years. The donors were identical sibling (3) , matched unrelated (1) and haploidentical family member (9) respectively. Nine patients reached partial remission and other remained no remission after chemotherapy before allo-HSCT. The median previous chemotherapy courses before allo-HSCT were 6 (2-13) . ② Conditioning regimen: Smostine 250 mg·m(-2)·d(-1), d-7; Cladribine 5 mg·m(-2)·d(-1), d-6 to d-2; Cytarabine Arabinoside 2 g·m(-2)·d(-1), d-6 to d-2; Busulfan 3.2 mg·m(-2)·d(-1), d-6 to d-3; Rabbit anti-human thymocyte immunoglobulin (ATG) 1.5 mg·m(-2)·d(-1) (unrelated donor transplantation) or 2.0-2.5 mg·m(-2)·d(-1) (haplo-HSCT) , d-4 to d-1. ③ Of the 12 patients, 11 patients attained complete haploidentical engraftment, one case occurred primary graft failure. The median durations for neutrophils and platelet implantations were 15 (15-21) and 19 (17-30) days respectively. ④After conditioning, no hepatic veno-occlusive diseases were observed, hemorrhagic cystitis occurred in 2 patients, 8 patients had fever, 3 cases experienced acute GVHD grade II, localized chronic GVHD occurred in 8 patients. ⑤The median follow-up was 8 (4-12) months. Leukemia relapse occurred in 2 patients at time of 6, 12 months after allo-HSCT. The estimated 1-year OS and DFS were (71.1±1.8) % and (62.2±1.8) %, respectively. Conclusions: allo-HSCT with cladribine sequential busulfan regimen was a feasible choice with favorable outcome for refractory/relapsed AML. 目的: 评估含克拉屈滨序预处理异基因造血干细胞移植(allo-HSCT)治疗难治/复发急性髓系白血病(AML)的疗效。 方法: 回顾性分析12例接受含克拉屈滨预处理allo-HSCT难治/复发AML患者的临床资料。 结果: ①12例患者中,男9例,女3例,中位年龄36(27~50)岁。亲缘全相合供者移植3例,无关供者移植1例,单倍型移植8例。移植前部分缓解9例,未缓解3例,移植前化疗中位疗程6(2~13)个。②预处理:司莫司汀250 mg·m(-2)·d(-1),-7 d;克拉屈滨5 mg·m(-2)·d(-1),-6 d~-2 d;阿糖胞苷2 g·m(-2)·d(-1),-6 d~-2 d;白消安3.2 mg·m(-2)·d(-1),-6 d~-3 d;兔抗人胸腺细胞免疫球蛋白(ATG)1.5 mg·m(-2)·d(-1)(无关供者移植)或2.0~2.5 mg·m(-2)·d(-1)(单倍型移植),-4 d~-1 d。③11例患者获得造血重建,1例发生原发植入失败。可评估患者中,中性粒细胞植入时间为15(15~21)d,中位血小板植入时间为19(17~30)d。④预处理过程中,12例患者均未发生肝静脉闭塞病,2例患者发生出血性膀胱炎。移植过程中8例出现发热,均经抗感染治疗后好转。3例患者发生Ⅱ度急性GVHD。至随访截止9例存活患者中8例发生慢性局限型GVHD。⑤中位随访时间为8(4~12)个月,2例患者分别在移植后6、12个月复发。预期1年总生存率为(71.1±1.8)%,无病生存率为(62.2±1.8)%。 结论: 含克拉屈滨预处理allo-HSCT可作为难治/复发AML患者的可选治疗方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ai H, Fu YW, Wang YQ, et al. [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31775481. doi:10.3760/cma.j.issn.0253-2727.2019.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。